Spectral Medical Announces First Quarter Results and Provides Corporate Update

Tigris Trial Enrollment Reaches 106 Patients

Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment

TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Read more at globenewswire.com